First Patient in Fibromyalgia Trial Dosed at Michigan University

In a recent development, a clinical-stage biotechnology firm, Tryp Therapeutics Inc., has achieved a significant milestone in its ongoing research. The company has successfully initiated dosing in a Phase 2a clinical trial for patients with fibromyalgia, in collaboration with the University of Michigan. The study is designed to assess the efficacy of TRP-8802, an oral psilocybin-based compound developed by Tryp, in conjunction with psychotherapy.

Jim Gilligan, the Chief Scientific Officer at Tryp Therapeutics, expressed enthusiasm about this advancement. He highlighted the potential benefits of TRP-8802 in fibromyalgia patients and hinted at the company's future plans to develop TRP-8803, an intravenous formulation of psilocin, which is the active metabolite of psilocybin. Gilligan explained that TRP-8803 is engineered to overcome several limitations associated with oral psilocybin, such as reducing the onset time of the psychedelic state, controlling the experience's intensity and duration, and shortening the intervention period to a more commercially viable length. The ultimate objective is to enhance outcomes for millions suffering from chronic pain, with a particular focus on reducing the reliance on opiates for pain management.

TRP-8802 serves as a precursor to TRP-8803, which features an innovative formulation and delivery mechanism. The drug candidate is intended to amplify the beneficial effects of psilocybin while significantly diminishing its drawbacks. Coupled with psychotherapy, TRP-8803 aims to treat a range of neuropsychiatric conditions, including fibromyalgia, binge eating disorder, and irritable bowel syndrome. Currently, Tryp is in the early stages of evaluating psilocybin-related compounds for these disorders using TRP-8802. Positive results from these trials will pave the way for further studies involving TRP-8803, which promises to improve efficacy, safety, and patient experience.

Tryp Therapeutics is dedicated to creating novel formulations for administering psilocin alongside psychotherapy to address diseases with unmet medical needs. The company's flagship program, TRP-8803, has already demonstrated promising results in a Phase 2a clinical trial for Binge Eating Disorder at the University of Florida, where it showed an average reduction in binge eating episodes exceeding 80%. In addition to the fibromyalgia trial at the University of Michigan, Tryp is gearing up for a Phase 2a clinical trial at Massachusetts General Hospital focused on abdominal pain and visceral tenderness in IBS patients.